-
2025-523230-77-00
4
2026-04-27
Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable t
-
2025-523231-19-00
4
2026-04-27
Cutaneous Squamous Cell Carcinoma
-
2025-523204-68-00
4
2026-03-25
HER2-positive breast cancer
-
2025-521884-12-00
5
2026-03-19
First line triple-negative breast cancer (TNBC)
-
2025-521797-34-00
5
2026-01-20
Diabetes Mellitus, Type 1
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2025-520982-39-00
5
2025-12-09
Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
-
2024-519795-11-00
4
2025-10-06
Atopic Dermatitis
-
2022-501867-42-01
9
2025-09-08
Acute Lymphoblastic Leukemia, in Relapse
Lymphoblastic Lymphoma (Precu
-
2022-501866-22-00
9
2025-08-26
Acute Lymphoblastic Leukemia, in Relapse
Lymphoblastic Lymphoma (Precu
-
2024-512360-55-00
4
2025-06-30
Unresectable locally recurrent or metastatic hormone receptor (HR)-pos
-
2024-511166-36-00
5
2025-06-13
Moderate to Severe Plaque Psoriasis
-
2024-515706-77-00
5
2025-05-08
Moderate to Severe Plaque Psoriasis
-
2023-507853-13-00
4
2025-02-25
Ulcerative Colitis
-
2024-512926-27-00
5
2024-12-12
patients with estrogen receptor-positive/human epidermal growth factor
-
2023-506602-39-00
6
2024-08-01
schizophrenia, schizoaffective disorder, schizophrenifom disorder
-
2023-504308-27-00
5
2024-06-06
non-squamous non-small cell lung cancer
-
2023-507402-13-00
5
2024-04-03
Multiple myeloma
-
2023-507039-39-00
5
2024-03-22
Moderate to Severe Plaque Psoriasis
-
2022-501157-36-00
6
2024-02-07
Critically ill patients who are dependent on high level medical care i
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2023-507031-38-00
5
2023-01-09
Severe viral lung infections
-
2022-501152-28-00
4
2022-12-21
Breast Cancer
-
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia